Account
Inquiry
QSC Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This synthetic peptide demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.
The molecular mechanism of QSC Tirzepatide involves simultaneous activation of both GIP and GLP-1 receptors, with preferential binding affinity for GIP receptors. This unique pharmacological profile results in enhanced glycemic control and significant metabolic benefits in preclinical studies.
Our QSC Tirzepatide is manufactured under strict quality control standards, with purity verified by HPLC analysis. Each batch is accompanied by comprehensive analytical documentation to ensure research reproducibility.
Key characteristics of our QSC Tirzepatide include high biological activity, excellent batch-to-batch consistency, and stability when stored under recommended conditions. The product is supplied as a lyophilized powder in various packaging options to meet different research requirements.
For research use only. Not for human consumption. This product is intended solely for laboratory research purposes by qualified professionals.
